<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594681</url>
  </required_header>
  <id_info>
    <org_study_id>4951-001</org_study_id>
    <nct_id>NCT04594681</nct_id>
  </id_info>
  <brief_title>A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability after administration of&#xD;
      KHK4951 in healthy volunteers and patients with wet age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Day 1 to Day 43</time_frame>
    <description>For adverse events that occurred after administration of the investigational drug, number of subjects with AEs and occurrence frequency are evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum KHK4951 concentration</measure>
    <time_frame>Healthy Volunteers: Day 1, Day2, Day4, Day8, Day12, Day16, Day21, Day23, Day 25, Day 29, Day 36, Day 43; Patients: Day 1, 8, 22, 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the maximum concentration</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum concentration</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KHK4951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered once daily or three times daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4951</intervention_name>
    <description>KHK4951 is administered once daily or three times daily.</description>
    <arm_group_label>KHK4951</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Healthy Volunteers&#xD;
&#xD;
          -  Voluntary written informed consent to participate in the study&#xD;
&#xD;
          -  Japanese or white men 20 to &lt; 50 years at the time of informed consent&#xD;
&#xD;
          -  BMI 18.5 to &lt; 30.0 at screening&#xD;
&#xD;
          -  Intraocular pressure (study eye) 10.0 mm Hg to 21.0 mm Hg&#xD;
&#xD;
          -  Monocular or binocular visual acuity (corrected visual acuity if correction is&#xD;
             required) ≥ 1.0 at screening&#xD;
&#xD;
        Inclusion Criteria: Patients&#xD;
&#xD;
          -  Voluntary written informed consent to participate in the study&#xD;
&#xD;
          -  Age ≥ 50 years at the time of informed consent&#xD;
&#xD;
          -  AMD-associated by active subfoveal CNV lesions in the study eye or juxtafoveal CNV&#xD;
             lesions with CNV-associated findings in the fovea in the study eye&#xD;
&#xD;
          -  CST ≥ 300 μm in the study eye at screening, as measured by OCT&#xD;
&#xD;
          -  BCVA score ≥ 23 letters in the study eye at screening and enrollment, as measured by&#xD;
             the ETDRS visual acuity chart&#xD;
&#xD;
          -  BCVA score ≥ 58 letters in the non-study eye at screening, as measured by the ETDRS&#xD;
             visual acuity chart&#xD;
&#xD;
          -  In subjects with prior treatment of the study eye with anti-vascular endothelial&#xD;
             growth factor (anti-VEGF) drugs such as Beovu, Eylea, Lucentis, Avastin, or Macugen,&#xD;
             presence of response to the anti-VEGF drug(s) as judged by the investigator or&#xD;
             subinvestigator based OCT, FA, visual acuity, or other assessment results&#xD;
&#xD;
        Exclusion Criteria: Healthy Volunteers&#xD;
&#xD;
          -  Current illness requiring treatment&#xD;
&#xD;
          -  History of ophthalmologic laser surgery, ophthalmologic surgery, nasolacrimal duct&#xD;
             surgery, orany eyelid surgery affecting flow in the nasolacrimal duct&#xD;
&#xD;
          -  History of or current circulatory disease (e.g., cerebrovascular or cardiovascular&#xD;
             disease)&#xD;
&#xD;
          -  History of or current dry eye&#xD;
&#xD;
          -  Abnormal findings on OCT at screening or enrollment examination&#xD;
&#xD;
        Exclusion Criteria: Patients&#xD;
&#xD;
          -  Clinical findings or a history of conditions other than wAMD affecting the retina and&#xD;
             choroid (e.g., diabetic retinopathy, diabetic macular edema, myopic CNV, retinal vein&#xD;
             occlusion, or premacular membrane) in either of the eyes&#xD;
&#xD;
          -  Any of the following diseases in the study eye:&#xD;
&#xD;
               -  Glaucoma&#xD;
&#xD;
               -  Ischemic optic neuropathy&#xD;
&#xD;
               -  Retinitis pigmentosa&#xD;
&#xD;
          -  Current or history of vitreous hemorrhage or macular hole in the study eye&#xD;
&#xD;
          -  Any abnormality in the anterior segment of the eye or vitreous body that may affect&#xD;
             fundus observation by OCT, color fundus photography, or fluorescein angiography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd.</last_name>
    <phone>+81-3-5205-7200</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hakata clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Kirin Co., Ltd.</last_name>
      <email>clinical.info.jp@kyowakirin.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

